ISOPTIN TAB 80MG TABLET

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

VERAPAMIL HYDROCHLORIDE

Inapatikana kutoka:

ABBOTT LABORATORIES, LIMITED

ATC kanuni:

C08DA01

INN (Jina la Kimataifa):

VERAPAMIL

Kipimo:

80MG

Dawa fomu:

TABLET

Tungo:

VERAPAMIL HYDROCHLORIDE 80MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

250

Dawa ya aina:

Prescription

Eneo la matibabu:

MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0113846002; AHFS:

Idhini hali ya:

CANCELLED POST MARKET

Idhini ya tarehe:

2007-07-31

Tabia za bidhaa

PRODUCT MONOGRAPH
ISOPTIN
®
(verapamil hydrochloride)
80 mg and 120 mg Tablets
_Antianginal/Antiarrhythmic/Antihypertensive Agent_
Abbott Laboratories, Limited
DATE OF PREPARATION:
8401 Trans Canada Highway
April 5, 2001
Saint-Laurent (QC) CANADA
H4S 1Z1
DATE OF REVISION:
February 19, 2004
Control No.: 088765
- 2 -
NAME OF DRUG
ISOPTIN
®
(verapamil hydrochloride)
80 mg and 120 mg Tablets
THERAPEUTIC CLASSIFICATION
Antianginal/Antiarrhythmic/Antihypertensive Agent
ACTION AND CLINICAL PHARMACOLOGY
ANGINA AND ARRHYTHMIA
ISOPTIN
®
(verapamil hydrochloride) is a calcium ion influx inhibitor (calcium
entry blocker or
calcium ion antagonist). The mechanism of the antianginal and
antiarrhythmic effects of verapamil
is believed to be related to its specific cellular action of
selectively inhibiting transmembrane influx
of calcium in cardiac muscle, coronary and systemic arteries and in
cells of the intracardiac
conduction system. Verapamil blocks the transmembrane influx of
calcium through the slow
channel (calcium ion antagonism) without affecting to any significant
degree the transmembrane
influx of sodium through the fast channel. This results in a reduction
of free calcium ions available
within cells of the above tissues.
Verapamil's antiarrhythmic effects are believed to be brought about
largely by its action on the
sinoatrial (S-A) and atrioventricular (A-V) nodes. Verapamil depresses
A-V nodal conduction and
prolongs functional refractory periods. Verapamil does not alter the
normal atrial action potential
or intraventricular conduction time, but depresses amplitude, velocity
of depolarization and
conduction in depressed atrial fibres. Through this action, it
interrupts re-entrant pathways and
slows the ventricular rate.
Verapamil may shorten the antegrade effective refractory period of the
accessory bypass tract.
Acceleration of ventricular rate and/or ventricular fibrillation has
been reported in patients with atrial
flutter or atrial fibrillation and a coexisting accessory A-V pathway
following administration